Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
Novavax Inc. stock outperforms competitors on strong trading day
Shares of Novavax Inc. NVAX climbed 17.99% to $8.33 Friday, on what proved to be an all-around favorable trading session for ...
Novavax call volume above normal and directionally bullish
Bullish option flow detected in Novavax (NVAX) with 9,851 calls trading, 2x expected, and implied vol increasing over 1 point to 83.26%. Jan-26 ...
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...
Novavax Inc. stock underperforms Thursday when compared to competitors
Novavax Inc. closed 70.41% below its 52-week high of $23.86, which the company reached on June 6th.
Novavax reports large quarterly revenue declines, rethinks its strategic direction
Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for ...
Novavax initiated with a Buy at BTIG
BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a ...
B. Riley Estimates Novavax’s FY2024 Earnings (NASDAQ:NVAX)
B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...
Novavax, Inc. (NASDAQ:NVAX) Shares Could Be 45% Below Their Intrinsic Value Estimate
Our fair value estimate is 8.2% lower than Novavax's analyst price target of US$16.43 How far off is Novavax, Inc. (NASDAQ:NVAX) from its intrinsic value? Using the most recent financial data, we'll ...
The Business Journals3d
Novavax execs lay out 2025 game plan, talk ‘defining moment’ for business
The company is on the lookout for partners to advance vaccine contenders. Novavax Inc. is starting to look like a vaccine development company again. The Gaithersburg biotech is two years into its ...